Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

Nicola Scichilone, Vincenzo Bellia, Pierluigi Paggiaro, Eugenio Sabato, Maria Teresa Busceti, Marchi, Segreti, Gianenrico Senna, Colombo, Ravazzi, Abbritti, Mario Cazzola, Marco Caminati, Manuela Latorre, Latorre, Palumbo, Paladini, Gundi Steinhilber, Maggi, Caterina BuccaAdriano Berra, Guarnieri, Scibilia, Letizia Vergura, Vergura, Macchia, Abbritti, Camiciottoli, Federica Novelli, Novelli, Vianello, Pierluigi Paggiaro, Cazzola, 5rottoli, Caminati, Pietro Schino, Alessandra Vultaggio, Alessandra Vultaggio, Anna Stanziola, Nicola Scichilone, Marco Bonavia, Gianna Camiciottoli, Gianna Camiciottoli, Alessandro Celi, Luigi Macchia, Baglioni, Andrea Matucci, Andrea Matucci, Maria Filomena Caiaffa, Caiaffa, Almerigogna, Paola Rottoli, Girolamo Pelaia, Vincenzo Bellia, Rosario Maselli, Di Gioacchino, Cecilia Calabrese, Piero Maestrelli, Gabriella Guarnieri, Guarnieri, Andrea Vianello, Pastorello, Bargagli, Cagnazzo

Risultato della ricerca: Articlepeer review

35 Citazioni (Scopus)

Abstract

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment.The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control.We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between poorly controlled and partially or well controlled asthmatics showed a statistically significant higher prevalence of some comorbidities in the first group, namely obesity, gastro-oesophageal reflux disease (GORD), aspirin intolerance and mental disorders (all p<0.001). Similarly, asthmatics with at least one exacerbation in the last year showed a significantly higher prevalence of obesity, chronic rhinosinusitis, nasal polyps, GORD, and aspirin intolerance (all p<0.05) than patients without exacerbations. When we selected patients without relevant comorbidities (upper airways disease, GORD, obesity, aspirin intolerance) and not currently smoking (. N=73), the percentage of well or partially controlled asthmatics was significantly higher than in patients with comorbidities (84.9% vs 71.1%, p=0.02); the rate of asthmatics without exacerbations in the last year was also higher (73.6% vs 51.1%, p=0.001).During omalizumab treatment, a high percentage of asthmatics obtain a good or partial control of asthma. Comorbidities are associated with the lack of asthma control and persistence of exacerbations.
Lingua originaleEnglish
pagine (da-a)123-129
Numero di pagine7
RivistaPULMONARY PHARMACOLOGY & THERAPEUTICS
Volume31
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2740???
  • ???subjectarea.asjc.2700.2704???
  • ???subjectarea.asjc.2700.2736???

Fingerprint

Entra nei temi di ricerca di 'Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy'. Insieme formano una fingerprint unica.

Cita questo